Brief: Tracon Pharmaceuticals Announces Submission Of Ind Application For Ctla-4 Antibody Yh001 For The Treatment Of Front-Line Sarcoma Patients In Combination With Envafolimab
08/08/2022 13:23
Aug 8 (Reuters) - TRACON Pharmaceuticals Inc TCON.O :
* TRACON PHARMACEUTICALS ANNOUNCES SUBMISSION OF IND
APPLICATION
FOR CTLA-4 ANTIBODY YH001 FOR THE TREATMENT OF FRONT-LINE
SARCOMA PATIENTS IN COMBINATION WITH ENVAFOLIMAB
Source text for Eikon: ID:nGNX3c4l6Q
Further company coverage: TCON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TRACON Pharmaceuticals
See all newsBrief: TRACON Pharmaceuticals Says ENVASARC Trial ORR Is 5%, Does Not Meet 11% Endpoint
Tracon Pharmaceuticals Inc Reports Results For The Quarter Ended In March: Earnings Summary
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Brief: Tracon Pharmaceuticals Files For Offering Of Common Stock, Pre-Funded Warrants